ADIPOQ and systemic sclerosis: Noticeably, a significant increase in the concentration of adiponectin during the treatment of systemic sclerosis with epoprostenol was shown, and this phenomenon may have a beneficial effect by inhibiting the progression of fibrosis in the course of the disease [54].